Tag: denosumab market trends

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Are The Future Growth Projections For The Denosumab Market Size?

The market for denosumab has seen swift expansion within the last few years. Forecasts suggest it will escalate from a size of $3.27 billion in 2024 to $3.67 billion in 2025, yielding a compound annual growth rate (CAGR) of 12.1%. Factors such as breakthroughs in clinical trials and research, FDA approvals and regulatory achievements, increasing consciousness about bone health, and strategic collaborations coupled with marketing efforts have driven the substantial growth during the historic period.

Expectations are set for a swift expansion in the denosumab market over the coming years, with forecasts predicting its growth to reach “$5.48 billion by 2029”, representing a compound annual growth rate (CAGR) of 10.6%. Factors contributing to this projected growth during the forecast period include the growing incidence of bone metastases, advancements in cancer treatments, the prevalence of osteoporosis, heightened public awareness of osteoporosis, and regulatory approvals for new indications. Other key trends during the forecast period include strategic collaborations and partnerships, integration with digital health solutions, expanded indications, and clinical applications, along with advancements in biosimilar development.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13835&type=smp

What Drivers Are Accelerating Expansion Of The Denosumab Market?

The growth of the denosumab market is projected to be catalyzed by the rising incidence of osteoporosis. Osteoporosis is a medical condition characterized by weakening of bones, which leads to decreased bone density and increased risk of fractures. Denosumab plays a crucial role in osteoporosis treatment as it prevents bone resorption by targeting the RANK ligand. For example, the National Center for Biotechnology Information, a government agency from the USA, reported in September 2023 through data from the Canadian Longitudinal Study on Aging that the prevalence of osteoporosis diagnosed by physicians was 12.7% and DXA-confirmed osteoporosis was 5.9% among older adults living in community settings. Also, a cross-sectional study conducted by Buttros and colleagues showed an osteoporosis prevalence rate of 24.6% in postmenopausal women aged between 40 to 75, determined using bone mineral density (BMD) tests. Thus, with the rise in osteoporosis prevalence, the denosumab market is experiencing significant growth.

What Segmentation Insights Are Provided In The Denosumab Market Research?

The denosumab market covered in this report is segmented –

1) By Drug Classification: Prolia, Xgeva, Others

2) By Type: 60 mg, 120 mg

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers

Which Notable Trends Are Transforming The Denosumab Market Outlook?

Leading companies within the denosumab market are intensifying their efforts to launch innovative solutions, such as primary treatments for osteoporosis, to secure an advantageous position in the marketplace. The term first-line treatment for osteoporosis denotes the initial or most preferred treatment strategy offered by healthcare professionals to individuals diagnosed with osteoporosis. For instance, in November 2022, approval was granted to Boan Biotech, a biotechnology company based in China, by China’s National Medical Products Administration (NMPA) for Boyoubei, its denosumab biosimilar. This achievement established Boan Biotech as the first Chinese company to create a denosumab injection. The firm is also developing for international markets beyond China, incorporating Europe and the United States, with plans for a global marketing strategy. This drug has been proposed as a primary treatment for osteoporosis in several treatment guidelines. It harbours the potential to greatly reduce the risk of hip, non-vertebral, and vertebral fractures in patients with osteoporosis. Moreover, Boyoubei is the world’s first biosimilar to Prolia, the original creator of denosumab, to be approved for marketing.

Who Are The Major Stakeholders Operating In The Denosumab Market?

Major companies operating in the denosumab market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Mylan N.V., Sandoz International GmbH, Daiichi Sankyo Company Limited, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Celltrion Inc., Amneal Pharmaceuticals Inc, Cadila Healthcare Limited, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Jubilant Life Sciences Limited, Ajanta Pharma Limited

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report

Which Regional Markets Are Emerging As Key Hubs For The Denosumab Market?

North America was the largest region in the denosumab market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=13835&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Denosumab Market Evolve in Terms of Growth and Size by 2029?

The market size for denosumab has experienced swift expansion in the past few years. The market is set to expand from $3.27 billion in 2024 to $3.67 billion in 2025, translating to a compound annual growth rate (CAGR) of 12.1%. Progress made in clinical trials and research, FDA endorsements and regulatory breakthroughs, increased consciousness about bone health, as well as strategic collaborations and marketing drives, have been the driving forces behind the growth during this historical period.

Rapid expansion is anticipated in the denosumab market size over the coming years. It is projected to swell to “$5.48 billion in 2029 with a compound annual growth rate (CAGR) of 10.6%. The forecast period’s growth is linked to the escalating occurrence of bone metastases, enhancements in cancer therapies, pervasive osteoporosis, elevated osteoporosis awareness, and regulatory approvals for new indications. The forecast period will also witness leading trends such as strategic alliances and partnerships, integration with digital health technologies, supplemental indications and clinical applications, and progression in biosimilar development.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13835&type=smp

What factors are expected to fuel Denosumab market growth in the coming years?

The escalating incidence of osteoporosis is anticipated to fuel the expansion of the denosumab market in the future. Osteoporosis is a health issue characterized by the weakening of bones, causing decreased bone density and an increased vulnerability to fractures. Denosumab is a treatment for osteoporosis that halts bone resorption by targeting the RANK ligand. For instance, data from the Canadian Longitudinal Study on Aging presented by the National Center for Biotechnology Information, a US-government agency, in September 2023, showed a 12.7% prevalence of osteoporosis diagnosed by physicians and a 5.9% DXA-confirmed prevalence in women living in communities among older adults. Moreover, a cross-sectional study carried out by Buttros and colleagues revealed a 24.6% prevalence of osteoporosis in postmenopausal women aged between 40 and 75, established through bone mineral density measurements. Hence, the rising incidence of osteoporosis is catalyzing the growth of the denosumab market.

The denosumab market covered in this report is segmented –

1) By Drug Classification: Prolia, Xgeva, Others

2) By Type: 60 mg, 120 mg

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers

Which Trends Are Redefining The Future Landscape Of The Denosumab Industry?

Leading establishments in the denosumab market are turning their attention towards the development of novel solutions, such as primary treatments for osteoporosis, to strengthen their position in the market. Primary treatment for osteoporosis signifies the first or primary treatment option advised by medical experts for managing patients with osteoporosis. To exemplify, Boan Biotech, a biotechnology firm based in China, was given the green light in November 2022 by China’s National Medical Products Administration (NMPA) for its denosumab biosimilar, Boyoubei, vaulting it into the position of being the first Chinese company to create a denosumab injection. The drug is also being prepared for sale in markets outside China, Europe and the United States included, with global marketing plans in place. Various treatment guidelines have recommended the drug as a primary treatment option for osteoporosis. This medication could potentially significantly reduce the likelihood of hip, non-vertebral and vertebral fractures in these patients. Furthermore, Boyoubei has the unique distinction of being the world’s first biosimilar to Prolia (the originator of denosumab) that has received marketing approval.

What Are The Most Active Companies In The Denosumab Market Today?

Major companies operating in the denosumab market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Mylan N.V., Sandoz International GmbH, Daiichi Sankyo Company Limited, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Celltrion Inc., Amneal Pharmaceuticals Inc, Cadila Healthcare Limited, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Jubilant Life Sciences Limited, Ajanta Pharma Limited

https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report

Which Regional Markets Are Attracting The Most Investment In Denosumab?

North America was the largest region in the denosumab market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13835&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Market Size of the Denosumab Market In 2029?

The market for denosumab has expanded swiftly in the last few years. It is projected to grow from $3.27 billion in 2024 to $3.67 billion in 2025, with a compound annual growth rate (CAGR) of 12.1%. The expansion in the preceding years can be credited to advancements in clinical trials and research, meeting regulatory milestones and FDA approvals, an increase in bone health consciousness, as well as strategic collaboration and marketing endeavors.

Expectations for the denosumab market size indicate a swift expansion in the upcoming years. The market is projected to reach $5.48 billion in 2029 with a compound annual growth rate (CAGR) of 10.6%. The anticipated advancement in the forecast period is due to factors such as an increase in bone metastases occurrences, enhancements in cancer treatments, widespread osteoporosis, heightened osteoporosis awareness, and regulatory green lights for new indications. Key trends for the forecast period encompass strategic alliances and partnerships, combination with digital health solutions, broadened indications and clinical applications, and upgrades in biosimilar development.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13835&type=smp

What Are the Primary Drivers Supporting the Market Growth of the Denosumab Market?

The denosumab market is anticipated to grow due to the escalating occurrence of osteoporosis. Osteoporosis is a health issue that weakens the bones, leading to decreased bone density and an elevated risk of fractures. Denosumab plays a role in treating osteoporosis by preventing bone resorption by zeroing in on the RANK ligand. As an example, data from the Canadian Longitudinal Study on Aging, released by the US-based National Center for Biotechnology Information in September 2023, revealed that physician-diagnosed osteoporosis prevalence was 12.7%, and DXA-confirmed osteoporosis stood at 5.9% in females among elder adults living in the community. Moreover, a cross-sectional study performed by Buttros and their team stated that osteoporosis was identified in 24.6% of postmenopausal women aged 40 to 75 using bone mineral density (BMD) measurements. Thus, the rising occurrence of osteoporosis is fueling denosumab market expansion.

Which Primary Segments of the Denosumab Market Are Driving Growth and Industry Transformations?

The denosumab market covered in this report is segmented –

1) By Drug Classification: Prolia, Xgeva, Others

2) By Type: 60 mg, 120 mg

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13835&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Denosumab Market?# Market?

North America was the largest region in the denosumab market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Most Significant Market Trends in the Denosumab Market?

Leading businesses in the denosumab market are intensifying their efforts towards the innovation of new solutions, like creating standard or prime treatment methods for osteoporosis, as a strategy to outrival other players in the market. Standard therapy for osteoporosis alludes to the frontline treatment course prescribed by medical experts for those suffering from osteoporosis. For instance, Boan Biotech, a biotech business based in China, in November 2022, was granted permission from the National Medical Products Administration (NMPA) of China to produce its denosumab biosimilar known as Boyoubei, hence becoming the pioneering Chinese company to formulate a denosumab injection. This drug is also being fashioned for markets outside China, such as Europe and the United States, and there are plans to market it globally. The drug is endorsed in various therapeutic guidelines as a standard therapy for osteoporosis. This medication could significantly reduce the likelihood of hip, non-vertebral, and vertebral fracture among patients. In addition, Boyoubei has the distinction of being the first biosimilar to Prolia (the original creator of denosumab) to receive worldwide marketing approval.

View the full report here:

https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report

What Parameters Are Used to Define the Denosumab Market?

Denosumab is a monoclonal antibody used to treat bone-related conditions, particularly osteoporosis and bone metastases. It works by inhibiting osteoclast formation, decreasing bone resorption, increasing bone mineral density, and reducing the risk of fracture.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13835

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the denosumab industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Is the Current and Projected Market Size of the Denosumab Market Through 2034?

In recent years, the denosumab market has seen substantial growth. The market, valued at $3.27 billion in 2024, is expected to rise to $3.7 billion in 2025, with a compound annual growth rate (CAGR) of 13.1%. The surge in growth during the historic period is a result of several factors, such as advancements in clinical research and trials, FDA approvals and regulatory milestones, increased awareness about bone health, along with strategic alliances and marketing drives.

In the coming years, the market size of denosumab is projected to undergo swift expansion. It is anticipated to escalate to $5.59 billion by 2029, with a compound annual growth rate (CAGR) of 10.9%. The propelling factors for growth in this projected timeframe include the increasing incidents of bone metastases, the development in cancer therapies, the prevalence of osteoporosis, heightened osteoporosis awareness, and regulation approval for new indications. Notable trends during the forecast period encompass strategic collaborations and alliances, digital health solutions integration, broadened indications and clinical applications, and progress in biosimilar creation.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13835&type=smp

What External and Internal Drivers Are Contributing to the Growth of the Denosumab Market?

The escalated occurrence of osteoporosis is anticipated to boost the development of the denosumab market. Essentially, osteoporosis is a health condition where the strength of bones decreases, leading to reduced bone density and a heightened possibility of fractures. Denosumab is employed to mitigate osteoporosis, by halting bone absorption via RANK ligand targeting. For example, data from the Canadian Longitudinal Study on Aging released by the National Center for Biotechnology Information, a U.S. government agency, in September 2023, indicated that the occurrence of osteoporosis diagnosed by physicians stood at 12.7%, while DXA-validated osteoporosis was at 5.9% among elderly adults residing in the community. Furthermore, a cross-sectional study conducted by Buttros and his team showed that the occurrence of osteoporosis in postmenopausal women aged between 40 to 75, diagnosed using bone mineral density (BMD) evaluations, was at 24.6%. As such, the rising occurrence of osteoporosis is spurring the expansion of the denosumab market.

What Segment Types Define the Denosumab Market Structure?

The denosumab market covered in this report is segmented –

1) By Drug Classification: Prolia, Xgeva, Others

2) By Type: 60 mg, 120 mg

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13835&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Denosumab Market?

North America was the largest region in the denosumab market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Denosumab Market?

Prominent firms in the denosumab market are ramping up their efforts to introduce innovative solutions, for instance, first-line therapies for osteoporosis, in a bid to secure a competitive advantage. The term “first-line treatment for osteoporosis” signifies the initial or prime therapeutic strategy suggested by healthcare practitioners for managing osteoporosis patients. Take for example, in November 2022, China’s Boan Biotech obtained approval from the National Medical Products Administration (NMPA) for its denosumab biosimilar, Boyoubei, becoming the debut Chinese firm to create a denosumab injection. The firm is also devising strategies for its introduction in markets beyond China, which include Europe and the United States, with an eye for global distribution. In several treatment guidelines, this drug has been advised as a first-line therapy for osteoporosis. The pharmaceutical holds the promise to substantially diminish the probability of hip, non-vertebral, and vertebral fractures in this category of patients. More so, Boyoubei stands as the world’s first biosimilar to Prolia (the original denosumab) with marketing approval.

View the full report here:

https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report

What Is the Definition of the Denosumab Market?

Denosumab is a monoclonal antibody used to treat bone-related conditions, particularly osteoporosis and bone metastases. It works by inhibiting osteoclast formation, decreasing bone resorption, increasing bone mineral density, and reducing the risk of fracture.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13835

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What External and Internal Drivers Are Contributing to the Growth of theDenosumab Market?

The denosumab market is set to experience growth due to the rising instances of osteoporosis. This medical condition, which weakens bones and increases the risk of fractures due to loss of bone density, is effectively treated with denosumab which targets RANK ligand to halt bone resorption. To illustrate, stats from the Canadian Longitudinal Study on Aging, reported by the National Center for Biotechnology Information, a US government agency in September 2023, showcased a 12.7% prevalence of osteoporosis with a physician’s diagnosis while osteoporosis confirmed through DXA stood at 5.9% among older adults living in the community. Furthermore, a study led by Buttros highlighted that out of postmenopausal women aged 40 to 75, 24.6% were diagnosed with osteoporosis after assessing bone mineral density (BMD) measurements. Hence, as the incidents of osteoporosis increase, it fuels the growth of the denosumab market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13835&type=smp

#What Growth Opportunities Will Drive the Denosumab Market’s CAGR Through 2034?

The market size of denosumab has witnessed a quick expansion in the past years. Its growth is projected to rise from $3.27 billion in 2024 to an impressive $3.7 billion in 2025, marking a compound annual growth rate (CAGR) of 13.1%. The notable increase during the historic period is due to valuable clinical trials and research developments, successful FDA approvals and regulatory achievements, amplified consciousness about bone health, along with strategic collaborations and marketing endeavors.

Anticipated expansion is expected in the denosumab market in the upcoming years, reaching a notable $5.59 billion by 2029, with a compound annual growth rate (CAGR) of 10.9%. Factors contributing to this growth during the forecast period include the escalating incidence of bone metastases, progress in cancer treatment methods, prevalent osteoporosis, heightened osteoporosis awareness, and regulatory acceptance for new indications. Key trends for the same period will be strategic alliances and collaborations, integration with digital health solutions, broader indications and clinical applications, and advancements in the development of biosimilars.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13835

Which Upcoming Market Trends and Innovations Are Set to Influence theDenosumab Market’s Path Forward?

Primary businesses in the denosumab market are intensifying their efforts to develop novel solutions like first-line osteoporosis treatments to establish an upper hand in the industry. A first-line treatment for osteoporosis is the preliminary procedure suggested by healthcare practitioners for individuals with an osteoporosis diagnosis. For example, in November 2022, China’s Boan Biotech received approval from the National Medical Products Administration (NMPA) for its denosumab biosimilar, Boyoubei, making it the pioneer Chinese company to create a denosumab injection. The company is also venturing into markets outside China, such as Europe and the US, with a global marketing strategy. Several treatment guidelines consider the drug as a primary treatment for osteoporosis. The treatment holds significant promise in reducing the likelihood of hip, non-vertebral, and vertebral fractures among patients. Moreover, Boyoubei is the first biosimilar to Prolia (the original denosumab) to gain approval for global marketing.

Who Are the Dominant Market Players Pushing the Boundaries of theDenosumab Market?

Major companies operating in the denosumab market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Mylan N.V., Sandoz International GmbH, Daiichi Sankyo Company Limited, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Celltrion Inc., Amneal Pharmaceuticals Inc, Cadila Healthcare Limited, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Jubilant Life Sciences Limited, Ajanta Pharma Limited

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report

What Are the Core Segments of the Denosumab Market, and How Do They Contribute to Growth?

The denosumab market covered in this report is segmented –

1) By Drug Classification: Prolia, Xgeva, Others

2) By Type: 60 mg, 120 mg

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=13835&type=smp

What Regions Are Dominating the Denosumab Market Growth?

North America was the largest region in the denosumab market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Denosumab Market 2025, By The Business Research Company:

Antifungals Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report

Antiobesity Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/antiobesity-global-market-report

Anemia And Other Blood Disorder Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the denosumab market grown over the years?

The market size for denosumab has quickly expanded in the last few years. It is set to increase from $3.27 billion in 2024 to $3.7 billion in 2025, marking a compound annual growth rate (CAGR) of 13.1%. The substantial growth seen in the historic period is owing to progress in clinical trials and research, regulatory achievements and FDA approvals, heightened awareness about bone health, along with strategic alliances and marketing efforts.

What Is the forecasted market size and growth rate for the denosumab market?

In the coming years, the market size for denosumab is anticipated to experience significant growth. The expected market value will be approximately $5.59 billion in 2029, showcasing a compound annual growth rate (CAGR) of 10.9%. The expected growth during the forecast period can be attributed to factors like the increasing prevalence of bone metastases, advancement in cancer therapies, and osteoporosis, increasing osteoporosis awareness, new indications’ regulatory approval, and more. In the forecast period, key trends will be strategic alliances and partnerships, digital health solutions integration, extended indications and clinical applications, and advancements in biosimilar development.

Get your denosumab market report here!

https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report

What are the major factors driving growth in the denosumab market?

The escalating incidence of osteoporosis is anticipated to spur the expansion of the denosumab market. Osteoporosis, a health disorder characterized by weakening of bones that leads to decreased bone density and elevated fracture risks, is addressed using denosumab which inhibits bone resorption by targeting the RANK ligand. For instance, statistics from the National Center for Biotechnology Information, a US government agency, revealed in September 2023 that data from the Canadian Longitudinal Study on Aging indicates physician-diagnosed osteoporosis had a prevalence of 12.7% and DXA-confirmed osteoporosis was at 5.9% among older adults living in communities, in females. Furthermore, a cross-sectional research conducted by Buttros and his team found a 24.6% prevalence of osteoporosis in postmenopausal women aged between 40 and 75, ascertained through bone mineral density (BMD) measurements. Consequently, the surging incidence of osteoporosis is stimulating the expansion of the denosumab market.

What key areas define the segmentation of the global denosumab Market?

The denosumab market covered in this report is segmented –

1) By Drug Classification: Prolia, Xgeva, Others

2) By Type: 60 mg, 120 mg

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13835&type=smp

What are the top market players propelling the growth of the denosumab industry?

Major companies operating in the denosumab market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Mylan N.V., Sandoz International GmbH, Daiichi Sankyo Company Limited, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Celltrion Inc., Amneal Pharmaceuticals Inc, Cadila Healthcare Limited, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Jubilant Life Sciences Limited, Ajanta Pharma Limited

What are the key trends shaping the future of the denosumab market?

Major enterprises active in the denosumab market are placing a heightened emphasis on pioneering new solutions, such as introducing primary treatments for osteoporosis, to gain an upper hand in the market. The initial or main therapeutic method suggested by healthcare experts for managing diagnosed osteoporosis patients is what is referred to as first-line treatment for osteoporosis. For instance, Boan Biotech, a biotech firm in China, got the green light from China’s National Medical Products Administration (NMPA) for its denosumab biosimilar, Boyoubei, in November 2022. This made it the first Chinese firm to create a denosumab injection. Efforts are underway to make it available in markets beyond China’s borders, including Europe and the US, with global marketing aims. The drug is endorsed as a primary osteoporosis treatment in various care guidelines. The medicine holds promise for significantly reducing the occurrence of hip, non-vertebral, and vertebral fractures in the patient group concerned. Moreover, Boyoubei is the first biosimilar of Prolia (the original denosumab) that’s gained approval for global marketing.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13835

What regions are dominating the denosumab market growth?

North America was the largest region in the denosumab market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Antifungals Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report

Antiobesity Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/antiobesity-global-market-report

Anemia And Other Blood Disorder Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Long-Term Growth Rate is Expected for the Denosumab Market Between 2025 and 2034?

There has been a swift expansion in the denosumab market size over the past few years. It is predicted that it will surge from $3.27 billion in 2024 to $3.7 billion in 2025, registering a compound annual growth rate (CAGR) of 13.1%. The upward trend during the historic period can be tied to factors such as advancements in clinical trials and research, FDA approvals and regulatory checkpoints, heightened awareness regarding bone health, along with strategic collaborations and marketing drives.

In the coming years, the market size for denosumab is predicted to expand rapidly. By 2029, it is forecasted to reach a worth of $5.59 billion with a compound annual growth rate (CAGR) of 10.9%. The expected growth within the forecast period can be tied to the increasing occurrences of bone metastases, progress in cancer treatments, the commonness of osteoporosis, and the augmented understanding of osteoporosis, together with regulatory green lights for new uses. Key trends within this period include strategic cooperation and partnerships, integration into digital health solutions, the growth of new uses and clinical applications, and advancements within biosimilar development.

Which Drivers Are Expected to Have the Greatest Impact on the denosumab Market’s Growth?

The growth of the denosumab market is anticipated to be boosted by the rising incidence of osteoporosis. Osteoporosis is a health condition which weakens the bones, leading to decreased bone density and increased fracture risk. Denosumab is employed in osteoporosis treatment by inhibiting bone resorption via the targeted RANK ligand. As indicated by data from the National Center for Biotechnology Information, a US governmental agency, the Canadian Longitudinal Study on Aging in September 2023 showed the prevalence of physician-diagnosed osteoporosis to be 12.7% and DXA-proven osteoporosis at 5.9% for female community-dwelling elderly. Furthermore, a cross-sectional study executed by Buttros et al revealed the incidence of osteoporosis in postmenopausal women aged between 40 and 75 to be 24.6%, diagnosed using bone mineral density (BMD) measurements. This surge in osteoporosis incidence is therefore propelling the denosumab market expansion.

Get Your Free Sample of the Global Denosumab Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=13835&type=smp

What Are the Key Firms That Are Driving Transformation in the Denosumab Market?

Major companies operating in the denosumab market report are:

• Johnson & Johnson_x000D_

• F. Hoffmann-La Roche Ltd._x000D_

• Novartis International AG_x000D_

• Sanofi SA_x000D_

• GlaxoSmithKline plc_x000D_

What Current Trends in the Denosumab Market Should Industry Players Pay Attention To?

Leading players in the denosumab market are striving to maintain their competitive stance by rolling out innovative solutions, including premier treatments for osteoporosis. The term “first-line treatment for osteoporosis” refers to the initial treatment method endorsed by medical practitioners for individuals diagnosed with the bone condition. As an example, in November 2022, China’s Boan Biotech secured approval from the country’s National Medical Products Administration (NMPA) for its denosumab biosimilar product, Boyoubei, becoming the first company in China to produce a denosumab injection. The company is also preparing it for markets beyond China, including Europe and the United States, with an aim to globally market it. Various treatment guidelines have suggested the drug as a superior treatment for osteoporosis. The drug potentially promises to significantly reduce the risk of hip, non-vertebral, and vertebral fractures among this group of patients. Moreover, Boyoubei is the world’s first biosimilar to Prolia (the original creator of denosumab) granted approval for global distribution.

Get Instant Access to the Global Denosumab Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report

Which Growth-Oriented Segments of the Denosumab Market Are Leading the Industry’s Development?

The denosumab market covered in this report is segmented –

1) By Drug Classification: Prolia, Xgeva, Others

2) By Type: 60 mg, 120 mg

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers

What Regions Are Driving Expansion in the Denosumab Market?

North America was the largest region in the denosumab market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Parameters Define the Denosumab Market’s Scope?

Denosumab is a monoclonal antibody used to treat bone-related conditions, particularly osteoporosis and bone metastases. It works by inhibiting osteoclast formation, decreasing bone resorption, increasing bone mineral density, and reducing the risk of fracture.

Browse Through More Similar Reports By The Business Research Company:

Antifungals Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report

Antiobesity Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/antiobesity-global-market-report

Anemia And Other Blood Disorder Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: